

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

**GRANT OF RESTRICTED SHARE UNITS PURSUANT TO
THE 2021 RSU SCHEME**

On September 4, 2024, the Company granted restricted share units pursuant to the 2021 RSU Scheme to eligible participants, detailed of which are set out in this announcement.

Sisram Medical Ltd (the “**Company**”) refers to (i) the Company’s announcements dated September 9, 2021 and December 2, 2021, (ii) the Company’s circulars dated October 26, 2021 and May 31, 2024, (iii) the poll results announcement of the extraordinary general meeting of the Company dated November 30, 2021 where Shareholders approved, among other things, the grant of a mandate to the directors of the Company (the “**Directors**”) to grant awards of restricted share units (the “**RSUs**”) to the Participants under the 2021 RSU Scheme, and (iv) the poll results announcement of the annual general meeting of the Company dated June 24, 2024 where Shareholders approved, among other things, the proposed amendments to the 2021 RSU Scheme. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the circular of the Company dated May 31, 2024.

Pursuant to Rule 17.06A, Rule 17.06B and Rule 17.06C of the Listing Rules, the board of directors of the Company (the “**Board**”) announces that on September 4, 2024 (the “**Grant Date**”), pursuant to the 2021 RSU Scheme, the Company granted an aggregate of 1,320,300 RSUs, representing an aggregate of 1,320,300 Shares (the “**Grant**”) to a total 59 Participants (the “**Grantees**”), subject to acceptance by the Grantees.

DETAILS OF THE GRANT

Details of the Grant are set out as follows:

Date of Grant	September 4, 2024
Total number of RSUs granted	1,320,300 RSUs (representing an aggregate of 1,320,300 Shares)
Number of Grantees	59
Category of Grantees	Employees of the Group
Purchase price	Nil

Closing price of the Shares on the Grant Date	HK\$3.42 per Share
Vesting period	The RSUs will be vested 12 months from the Grant Date.
Performance targets	The Grant of the RSUs shall be conditional on the achievement of objective performance conditions as set out in the Notice of Grant, which include measures relating to financial metrics and other targets (such as net profits attributable to owners and R&D expenses of the Company for 2024)
Clawback mechanism	There is no clawback mechanism to recover any Shares already delivered to Grantees in accordance with the 2021 RSU Scheme. None of the Grantees are Directors or senior management of the Company.
Financial assistance	No financial assistance has been provided by the Group to the Grantees to facilitate the purchase of Shares under the 2021 RSU Scheme.

REASONS FOR AND BENEFITS OF THE GRANT

The purpose of the Grant is to effectively attract and retain core talents who have significant influence on and contribution to the Company's business growth, to stimulate the entrepreneurial passion of core and key employees, and to support the long-term development of the Company. The Grant is also in the interests of the Company and the Shareholders as a whole. All of the Grantees are new grantees who had not previously received any grant of RSUs pursuant to the 2021 RSU Scheme. There are no overlaps between the new Grantees and the grantees mentioned in the Company's announcements dated September 9, 2021 and December 2, 2021.

LISTING RULES IMPLICATIONS

To the best knowledge of the Directors, none of the Grantees is (i) a Director, chief executive or substantial shareholder of the Company, or any of their associates (as defined under the Listing Rules); (ii) a participant with options and awards granted and to be granted exceeding the 1% individual limit under the Listing Rules; or (iii) a related entity participant or service provider with options and awards granted and to be granted in any 12-month period exceeding 0.1% of the total number of issued shares (excluding treasury shares). The Grant is not subject to approval by the Shareholders.

NUMBER OF SHARES AVAILABLE FOR FUTURE GRANT

The maximum aggregate number of shares that may be issued under the 2021 RSU Scheme shall not exceed 22,107,780 Shares, representing 4.7% of the total number of issued Shares on the date of this announcement. After the above Grant, 17,632,279 RSUs will be available for future grants under the Scheme Mandate Limit.

By Order of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Yi LIU
Chairman

Hong Kong, September 4, 2024

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU and Mr. Lior Moshe DAYAN as executive Directors; Mr. Yifang WU and Ms. Rongli FENG as non-executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive Directors.

* *for identification purpose only*